Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70(5):1469–1480
Article CAS PubMed Google Scholar
Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C et al (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15(13):2445–2453
Article CAS PubMed Google Scholar
Rabinowitz MH (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem 56(23):9369–9402
Article CAS PubMed Google Scholar
Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G et al (2021) Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384(17):1589–1600
Article CAS PubMed Google Scholar
Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL et al (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385(25):2313–2324
Article CAS PubMed Google Scholar
Zheng L, Tian J, Liu D, Zhao Y, Fang X, Zhang Y et al (2022) Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis. Br J Clin Pharmacol 88(3):919–932
Article CAS PubMed Google Scholar
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T (2021) Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. Am J Nephrol 52(10–11):871–883
Article CAS PubMed Google Scholar
Haase VH (2011) Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease (2011). Kidney Int Suppl 11(1):8–25
Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ et al (2014) Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1alpha. Am J Respir Crit Care Med 189(3):314–324
Article PubMed PubMed Central Google Scholar
Shimoda LA (1985) Laurie SS 2014 HIF and pulmonary vascular responses to hypoxia. J Appl Physiol 116(7):867–74
Bishop T, Ratcliffe PJ (2015) HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res 117(1):65–79
Article CAS PubMed PubMed Central Google Scholar
Imamura T, Hori M, Tanaka S, Kinugawa K (2021) Impact of hypoxia-inducible factor prolyl hydroxylase inhibitor on heart failure with preserved ejection fraction. Medicina (Kaunas) 57(12):1319
Liu P, Wang L, DuBois BG, Colandrea VJ, Liu R, Cai J et al (2018) Discovery of orally bioavailable and liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. ACS Med Chem Lett 9(12):1193–1198
Article CAS PubMed PubMed Central Google Scholar
Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y et al (2020) Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Pharmacol Res 159:105020
Article CAS PubMed Google Scholar
Zhong H, Zhou T, Li H, Zhong Z (2018) The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Des Devel Ther 12:3003–3011
Article CAS PubMed PubMed Central Google Scholar
Zhang S, Guo J, Xie S, Chen J, Yu S, Yu Y (2021) Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis. Int Urol Nephrol 53(6):1139–1147
Article CAS PubMed Google Scholar
Russell WMS, Burch RL (1960) The principles of humane experimental technique. Med J Australia 1:500. https://doi.org/10.5694/j.1326-5377.1960.tb73127.x
Debenham JS, Madsen-Duggan C, Clements MJ, Walsh TF, Kuethe JT, Reibarkh M et al (2016) Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1–3 (HIF PHD1-3) for the Treatment of Anemia. J Med Chem 59(24):11039–11049
Article CAS PubMed Google Scholar
Hurford WE, Crosby G, Strauss HW, Jones R, Lowenstein E (1990) Ventricular performance and glucose uptake in rats during chronic hypobaric hypoxia. J Nucl Med 31(8):1344–1351
Smith KA, Waypa GB, Dudley VJ, Budinger GRS, Abdala-Valencia H, Bartom E et al (2020) Role of Hypoxia-inducible factors in regulating right ventricular function and remodeling during chronic hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 63(5):652–664
Article CAS PubMed PubMed Central Google Scholar
Vanliere EJ, Krames BB, Northup DW (1965) Differences in cardiac hypertrophy in exercise and in hypoxia. Circ Res 16:244–248
Article CAS PubMed Google Scholar
Naghshin J, McGaffin KR, Witham WG, Mathier MA, Romano LC, Smith SH et al (2009) Chronic intermittent hypoxia increases left ventricular contractility in C57BL/6J mice (1985). J Appl Physiol 107(3):787–93
Article CAS PubMed PubMed Central Google Scholar
Naghshin J, Rodriguez RH, Davis EM, Romano LC, McGaffin KR, O’Donnell CP (2012) Chronic intermittent hypoxia exposure improves left ventricular contractility in transgenic mice with heart failure (1985). J Appl Physiol 113(5):791–8
Article CAS PubMed PubMed Central Google Scholar
Kerkela R, Karsikas S, Szabo Z, Serpi R, Magga J, Gao E et al (2013) Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol Cell Biol 33(16):3321–3329
Article CAS PubMed PubMed Central Google Scholar
Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler AA 3rd (2006) Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 98(1):133–140
Article CAS PubMed Google Scholar
Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G et al (2008) Short hairpin RNA interference therapy for ischemic heart disease. Circulation 118(14 Suppl):S226–S233
CAS PubMed PubMed Central Google Scholar
Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM (2001) Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104(18):2216–2221
Article CAS PubMed Google Scholar
Philipp S, Jurgensen JS, Fielitz J, Bernhardt WM, Weidemann A, Schiche A et al (2006) Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail 8(4):347–354
Article CAS PubMed Google Scholar
Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL et al (2010) Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 56(2):147–155
Article CAS PubMed Google Scholar
Philipp SFJ, Bernhardt WM, Jürgensen JS, Schuch E et al (2013) Induction of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function and reduces left ventricular hypertrophy after aortocaval shunt in rats. J Clin Exp Cardiolog 4(1):6
Signore PE, Guo G, Wei Z, Zhang W, Lin A, Del Balzo U (2021) A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. PLoS ONE 16(8):e0255022
Article CAS PubMed PubMed Central Google Scholar
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219
Comments (0)